BioCardia dropped a planned IPO in April. Now, it’s back with a reverse merger into medical device shell company Tiger X Medical.

Gilead and Galapagos have hit go on a Phase III trial program for their rheumatoid arthritis drug, filgotinib.

As the dust settles on the eye-watering $14 billion buyout from Pfizer for the one-marketed-drug biotech Medivation, other mid-cap companies are now sitting…

Perceptive Advisors has co-led a $14 million Series C financing to get startup Vyome into clinical testing with its lead candidate to treat antibiotic-…

Regeneron Pharmaceuticals and the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) have…

Partners Eli Lilly and AstraZeneca got a leap ahead in the BACE inhibitor race as they secure a fast-track designation from the FDA for Phase III candidate…

The privately owned Dublin, Ireland-based DS Biopharma has spun out a company from its ranks in order for it to focus specifically on scarring diseases, while…

Biotech Thar Pharmaceuticals is gunning for a $50 million IPO as it looks to launch its first pivotal trial in 2017 for an oral form of a marketed bone drug…